Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...
Jul
20
2023
VIRTUAL
10:00—11:00 AM ET / 3:00-4:00 PM BST
June 14, 2023
Join the Center for Global Development for a virtual panel discussion reflecting on lessons learned from COVAX for future global and regional response efforts to ensure rapid and equitable access to vaccines and other medical countermeasures.
Blog Post
March 07, 2023
The EU and its member states are collectively the world’s largest aid donor, with an annual budget of over $70 billion in 2021. When it comes to global health, however, it has historically punched below its weight. In part, this is due to an internal coordination problem; health is a shared competen...
Mar
7
2023
VIRTUAL
9:30—10:45 AM Eastern Time (US and Canada)
February 27, 2023
Following promising clinical trial results, the first oral antiviral treatments for COVID-19 received emergency use authorization in late 2021. Since then, manufacturers, global health funders, and other partners have focused on ramping up global supply, including via test-and-treat pilot programs. ...
Blog Post
December 14, 2022
It’s clear that COVID-19 oral antivirals are effective, and recent deals have made them even cheaper for African countries. But should these countries be investing in these medicines? Or would spending on alternative health services be better value for money? Unfortunately, there is very little avai...
CGD NOTES
December 14, 2022
Almost a year after two oral antiviral treatments received emergency use authorization, demand is extremely low. In this note, we argue that governments and their donor partners should use data and evidence to consider the economic and clinical rationale for registering, financing, purchasing, and d...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.
Blog Post
August 10, 2022
PEPFAR’s new strategy—to be released in final form later this year—focuses on how to accelerate progress toward epidemic control amidst continued impacts from COVID-19, while also strengthening core health system functions as well as partnership and coordination efforts; this is precisely what the c...
Blog Post
June 10, 2022
In June 2021, Dr. Tedros Ghebreyesus, offered a challenge to the world: “To truly end the pandemic, our goal must be to vaccinate at least 70 percent of the world’s population by the time you meet again in Germany next year.” However, as we approach this year’s G7 summit, the 70 percent target has b...